Verano, Green Thumb & MariMed's Strong Q2: Unpacking The Cannabis Earnings Surge
Portfolio Pulse from Nicolás Jose Rodriguez
Pablo Zuanic of Zuanic & Associates analyzed the Q2 2024 performance of Verano Holdings, Green Thumb Industries, and MariMed Inc. Verano saw a 6% revenue increase due to strategic acquisitions, Green Thumb's revenue grew 10% with strong free cash flow, and MariMed reported a 4% revenue increase with a focus on organic growth.
August 16, 2024 | 10:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Green Thumb Industries saw a 10% year-over-year revenue increase to $335 million in Q2 2024, maintaining an adjusted EBITDA margin of 32.5% and generating strong free cash flow of $45 million.
Green Thumb's strong revenue growth, stable EBITDA margin, and significant free cash flow suggest robust financial health, likely leading to a positive short-term stock price impact.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
POSITIVE IMPACT
MariMed Inc. reported a 4% year-over-year revenue increase to $37 million in Q2 2024, with an improved EBITDA margin of 20.4%. The company focuses on organic growth and refrains from share buybacks.
MariMed's modest revenue growth and improved EBITDA margin indicate steady financial performance, likely resulting in a positive short-term stock price impact.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Verano Holdings reported a 6% quarter-over-quarter revenue increase to $233 million, driven by strategic acquisitions in Virginia and Arizona. The adjusted EBITDA margin improved slightly to 36.2%.
Verano's revenue growth and improved EBITDA margin indicate positive financial health, likely boosting investor confidence and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100